DHR Health Institute for Research and Development
12
1
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.7%
2 terminated/withdrawn out of 12 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
60%
3 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Role: collaborator
VIGOR: Virtual Genome Center for Infant Health
Role: collaborator
Enriched Environments in Endometriosis
Role: collaborator
Evaluating Pharmacogenomic Variants for Cardiology Therapeutics
Role: collaborator
Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With T2 Diabetes
Role: collaborator
Breast Cancer Liquid Biopsy Trial
Role: collaborator
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
Role: lead
Online Spanish Cognitive Intervention Program for Spanish-Speaking Latino/Hispanic Subarachnoid Hemorrhage Patients
Role: lead
"Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance
Role: lead
Exoskeleton Rehabilitation on TBI
Role: lead
Omegaven Protocol:Intermediate Size Patient Population
Role: lead
Multidisciplinary Team Approach: Working Together to Improve Glycemic Control in Hispanic Adults Diabetes
Role: collaborator
All 12 trials loaded